Fingolimod treatment promotes regulatory phenotype and function of B cells

Annals of Clinical and Translational Neurology

Volumn 2, Issue 2, 2015, Pages 119-130

  Grützke, Berit ^a   Hucke, Stephanie ^a   Gross, Catharina C ^a   Herold, Martin V B ^a   Posevitz Fejfar, Anita ^a   Wildemann, Brigitte T ^b   Kieseier, Bernd C ^c   Dehmel, Thomas ^c   Wiendl, Heinz ^a   Klotz, Luisa ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD24 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; CD5 ANTIGEN; FINGOLIMOD; INTERLEUKIN 10;

ADULT; ARTICLE; B LYMPHOCYTE SUBPOPULATION; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; CELL FUNCTION; CELL MIGRATION; CEREBROSPINAL FLUID; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL;

EID: 84932615567     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.155     Document Type: Article

References (28)

1. Mann MK, Ray A, Basu S, et al. Pathogenic and regulatory roles for B cells in experimental autoimmune encephalomyelitis. Autoimmunity 2012;45:388–399.
2. Weber MS, Prod'homme T, Patarroyo JC, et al. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol 2010;68:369–383.
3. Ireland SJ, Blazek M, Harp CT, et al. Antibody-independent B cell effector functions in relapsing remitting multiple sclerosis: clues to increased inflammatory and reduced regulatory B cell capacity. Autoimmunity 2012;45:400–414.
4. Fillatreau S, Gray D, Anderton SM. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol 2008;8:391–397.
5. Duddy M, Niino M, Adatia F, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007;178:6092–6099.
6. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427:355–360.
7. Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010;9:883–897.
8. Kowarik MC, Pellkofer HL, Cepok S, et al. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology 2011;76:1214–1221.
9. Blair PA, Norena LY, Flores-Borja F, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010;32:129–140.
10. Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol 2012;30:221–241.
11. Nakamura M, Matsuoka T, Chihara N, et al. Differential effects of fingolimod on B-cell populations in multiple sclerosis. Mult Scler 2014;20:1371–1380.
12. Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008;71:1261–1267.
13. Mehling M, Lindberg R, Raulf F, et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 2010;75:403–410.
14. Pham TH, Okada T, Matloubian M, et al. S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. Immunity 2008;28:122–133.
15. Von Bergwelt-Baildon M, Shimabukuro-Vornhagen A, Popov A, et al. CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood 2006;107:2786–2789.
16. Fillatreau S, Sweenie CH, McGeachy MJ, et al. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002;3:944–950.
17. Mauri C, Gray D, Mushtaq N, Londei M. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003;197:489–501.
18. Hirotani M, Niino M, Fukazawa T, et al. Decreased IL-10 production mediated by Toll-like receptor 9 in B cells in multiple sclerosis. J Neuroimmunol 2010;221:95–100.
19. Carter NA, Vasconcellos R, Rosser EC, et al. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol 2011;186:5569–5579.
20. Matsumoto M, Fujii Y, Baba A, et al. The calcium sensors STIM1 and STIM2 control B cell regulatory function through interleukin-10 production. Immunity 2011;34:703–714.
21. Hussain S, Delovitch TL. Intravenous transfusion of BCR-activated B cells protects NOD mice from type 1 diabetes in an IL-10-dependent manner. J Immunol 2007;179:7225–7232.
22. Flores-Borja F, Bosma A, Ng D, et al. CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med 2013;5:173ra23.
23. Haas J, Bekeredjian-Ding I, Milkova M, et al. B cells undergo unique compartmentalized redistribution in multiple sclerosis. J Autoimmun 2011;37:289–299.
24. Liu C, Noorchashm H, Sutter JA, et al. B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat Med 2007;13:1295–1298.
25. Garris CS, Wu L, Acharya S, et al. Defective sphingosine 1-phosphate receptor 1 (S1P) phosphorylation exacerbates T17-mediated autoimmune neuroinflammation. Nat Immunol 2013;14:1166–1172.
26. Sawicka E, Dubois G, Jarai G, et al. The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity. J Immunol 2005;175:7973–7980.
27. Arnon TI, Horton RM, Grigorova IL, Cyster JG. Visualization of splenic marginal zone B-cell shuttling and follicular B-cell egress. Nature 2013;493:684–688.
28. Schwab N, Hohn KG, Schneider-Hohendorf T, et al. Immunological and clinical consequences of treating a patient with natalizumab. Mult Scler 2012;18:335–344.